Heart failure update

CPD Questionnaire

EARN FREE CPD POINTS

Complete, scan and email to **cpd@denovomedica.com**. Alternatively, you can complete this questionnaire online at **www.denovomedica.com**. Fill in your details using **clear block letters** and mark the answers with a tick (✓).

I agree that my CPD-accredited certificate will be forwarded to my e-mail address. _____
(Signature of healthcare professional)

(Online)

First Name		**Profession**	
Surname		**Telephone**	
HPC No.		**City**	
E-mail			

1. Heart failure mortality rates are higher than cancer mortality rates.

☐ **A** True ☐ **B** False

2. The lifetime risk of heart failure at age 55 years is ___ for men.

☐ **A** 22% ☐ **B** 28% ☐ **C** 33%

3. Which statement is incorrect? With respect to heart failure:

☐ **A** Typical symptoms include breathlessness, ankle swelling and fatigue
☐ **B** Typical signs include pulmonary congestion and peripheral oedema
☐ **C** Diuretic therapy provides long-term prevention of death

4. The most common heart failure presentation is:

☐ **A** HFrEF ☐ **B** HFpEF ☐ **C** HFmrEF

5. Which statement is correct? With respect to heart failure:

☐ **A** BNP or proBNP levels will be low ☐ **B** BNP can be falsely positive and elevated ☐ **C** A and B

6. Targets for heart failure drug intervention include:

☐ **A** Decreased stroke volume ☐ **B** Activation of RAAS ☐ **C** Activation of sympathetic nervous system
☐ **D** All of the above ☐ **E** A and B only ☐ **F** B and C only

7. Beta blockers are contraindicated in the patient with heart failure.

☐ **A** True ☐ **B** False

8. Activation of the sympathetic nervous system by ACE-inhibitors leads to:

☐ **A** Decreased heart rate ☐ **B** Activated RAAS ☐ **C** Electrolyte abnormalities
☐ **D** Cytokine activation ☐ **E** All of the above ☐ **F** B, C and D only

9. Which statement is incorrect? With respect to heart rate:

☐ **A** The lower the heart rate is in heart failure, the worse the outcome
☐ **B** Dihydropyridine CCBs are absolutely contraindicated and are unsafe for use in HFrEF
☐ **C** Ivabradine may have a specific role in a small subset of patients with heart failure

10. The CIBIS II study of beta blocker therapy demonstrated that, as compared to placebo, bisoprolol reduced mortality by ___.

☐ **A** 23% ☐ **B** 28% ☐ **C** 34%

11. The CIBIS II study demonstrated that, as compared to placebo, bisoprolol reduced:

☐ **A** Sudden death ☐ **B** Hospital admissions ☐ **C** Hospital admissions for worsening heart failure
☐ **D** All of the above ☐ **E** A and B only ☐ **F** A and C only

12. The range of effects of beta blockers in heart failure include:

☐ **A** Antiarrhythmic activity ☐ **B** Reduction of sympathetic tone ☐ **C** Antagonism of stimulatory autoantibodies
☐ **D** Modification of remodelling ☐ **E** All of the above ☐ **F** A, B and D only

13. There is an evidence base that spironolactone increases heart failure survival in patients with HFrEF.

☐ **A** True ☐ **B** False

14. Which statement is correct?

☐ **A** Spironolactone is safe for use in patients with kidney dysfunction
☐ **B** The current standard of treatment of heart failure is ARNI therapy
☐ **C** MRA therapy is recommended for heart failure patients who cannot access ARNI therapy

15. Which statement is incorrect? With respect to SGLT-2 inhibitors, benefit for heart failure patients has been demonstrated in those:

☐ **A** With diabetes ☐ **B** Without diabetes ☐ **C** A and B

© 2021 deNovo Medica